Pentosan Polysulfate Treatment's Effectiveness

Hisar Intercontinental Hospital

Status: Completed

Conditions: Chronic Interstitial Cystitis

Treatments: Other: Pentosan Polysulphate

Study type: Interventional

Funder types: Other

Identifiers

NCT05744908

10.01.2023/37

Details and patient eligibility

About

To examine the relationship between symptoms and quality of life before and after oral pentosan polysulfate (PPS) treatment in cases diagnosed with interstitial cystitis/painful bladder syndrome (IC/BPS).

Full description

Demographic characteristics, medical history, clinical conditions, and laboratory and cystoscopic data of patients who applied to our clinic between January 2018 and December 2021 and were diagnosed with IC/BPS were retrospectively analyzed. Adult male and female patients with IC/BPS who received 300 mg/day PPS at least six months ago with complaints of pain, urge, frequency, and nocturia not associated with urinary tract infection were included in the study. In addition, pre- and post-treatment symptoms, ICSI scores, quality of life (scored between 1-4), and satisfaction were compared.

Enrollment: 37 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Chronic interstitial cystitis
• Bladder Pain Syndrome

Exclusion criteria

• Acute cystitis
• Bladder cancer
• Chronic prostatitis
• Bladder stone
• Stress incontinence

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Single Blind

---

37 participants in 2 patient groups

With Hunner's ulcer

Active Comparator group

Description:

Pentosan Polysulfate 100 mg

Treatment:

Other: Pentosan Polysulphate

Without Hunner's ulcer

Active Comparator group

Description:

Pentosan Polysulfate 100 mg

Treatment:

Other: Pentosan Polysulphate